Peptide-induced antiviral protection by cytotoxic T cells.
PDF (491K)
Journal: 1991/March - Proceedings of the National Academy of Sciences of the United States of America
ISSN: 0027-8424
PUBMED: 1992491
Abstract:
A specific antiviral cytotoxic immune response in vivo could be induced by the subcutaneous injection of the T-cell epitope of the lymphocytic choriomeningitis virus (LCMV) nucleoprotein as an unmodified free synthetic peptide (Arg-Pro-Gln-Ala-Ser-Gly-Val-Tyr-Met-Gly-Asn-Leu-Thr-Ala-Gln) emulsified in incomplete Freund's adjuvant. This immunization rendered mice into a LCMV-specific protective state as shown by the inhibition of LCMV replication in spleens of such mice. The protection level of these mice correlated with the ability to respond to the peptide challenge by CD8+ virus-specific cytotoxic T cells. This is a direct demonstration that peptide vaccines can be antivirally protective in vivo, thus encouraging further search for appropriate mixtures of stable peptides that may be used as T-cell vaccines.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(56)
References
(16)
Diseases
(1)
Chemicals
(4)
Organisms
(6)
Processes
(2)
Anatomy
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Proc Natl Acad Sci U S A 88(3): 991-993
PMID: 1992491

Peptide-induced antiviral protection by cytotoxic T cells.

Abstract

A specific antiviral cytotoxic immune response in vivo could be induced by the subcutaneous injection of the T-cell epitope of the lymphocytic choriomeningitis virus (LCMV) nucleoprotein as an unmodified free synthetic peptide (Arg-Pro-Gln-Ala-Ser-Gly-Val-Tyr-Met-Gly-Asn-Leu-Thr-Ala-Gln) emulsified in incomplete Freund's adjuvant. This immunization rendered mice into a LCMV-specific protective state as shown by the inhibition of LCMV replication in spleens of such mice. The protection level of these mice correlated with the ability to respond to the peptide challenge by CD8+ virus-specific cytotoxic T cells. This is a direct demonstration that peptide vaccines can be antivirally protective in vivo, thus encouraging further search for appropriate mixtures of stable peptides that may be used as T-cell vaccines.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (491K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
icon of scanned page 991
991
icon of scanned page 992
992
icon of scanned page 993
993

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Staerz UD, Karasuyama H, Garner AM. Cytotoxic T lymphocytes against a soluble protein. Nature. 1987 Oct 1;329(6138):449–451. [PubMed] [Google Scholar]
  • Carbone FR, Bevan MJ. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J Exp Med. 1989 Mar 1;169(3):603–612.[PMC free article] [PubMed] [Google Scholar]
  • Ishioka GY, Colon S, Miles C, Grey HM, Chesnut RW. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo. J Immunol. 1989 Aug 15;143(4):1094–1100. [PubMed] [Google Scholar]
  • Deres K, Schild H, Wiesmüller KH, Jung G, Rammensee HG. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature. 1989 Nov 30;342(6249):561–564. [PubMed] [Google Scholar]
  • Takahashi H, Takeshita T, Morein B, Putney S, Germain RN, Berzofsky JA. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature. 1990 Apr 26;344(6269):873–875. [PubMed] [Google Scholar]
  • Buchmeier MJ, Welsh RM, Dutko FJ, Oldstone MB. The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol. 1980;30:275–331. [PubMed] [Google Scholar]
  • Aichele P, Hengartner H, Zinkernagel RM, Schulz M. Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide. J Exp Med. 1990 May 1;171(5):1815–1820.[PMC free article] [PubMed] [Google Scholar]
  • Lehmann-Grube F, Ambrassat J. A new method to detect lymphocytic choriomeningitis virus-specific antibody in human sera. J Gen Virol. 1977 Oct;37(1):85–92. [PubMed] [Google Scholar]
  • Schulz M, Aichele P, Vollenweider M, Bobe FW, Cardinaux F, Hengartner H, Zinkernagel RM. Major histocompatibility complex--dependent T cell epitopes of lymphocytic choriomeningitis virus nucleoprotein and their protective capacity against viral disease. Eur J Immunol. 1989 Sep;19(9):1657–1667. [PubMed] [Google Scholar]
  • Cobbold SP, Jayasuriya A, Nash A, Prospero TD, Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984 Dec 6;312(5994):548–551. [PubMed] [Google Scholar]
  • Hany M, Oehen S, Schulz M, Hengartner H, Mackett M, Bishop DH, Overton H, Zinkernagel RM. Anti-viral protection and prevention of lymphocytic choriomeningitis or of the local footpad swelling reaction in mice by immunization with vaccinia-recombinant virus expressing LCMV-WE nucleoprotein or glycoprotein. Eur J Immunol. 1989 Mar;19(3):417–424. [PubMed] [Google Scholar]
  • Welsh RM, Jr, Zinkernagel RM. Heterospecific cytotoxic cell activity induced during the first three days of acute lymphocytic choriomeningitis virus infection in mice. Nature. 1977 Aug 18;268(5621):646–648. [PubMed] [Google Scholar]
  • Herberman RB, Djeu J, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, Puccetti P. Natural killer cells: characteristics and regulation of activity. Immunol Rev. 1979;44:43–70. [PubMed] [Google Scholar]
  • Pircher H, Moskophidis D, Rohrer U, Bürki K, Hengartner H, Zinkernagel RM. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature. 1990 Aug 16;346(6285):629–633. [PubMed] [Google Scholar]
  • Whitton JL, Gebhard JR, Lewicki H, Tishon A, Oldstone MB. Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J Virol. 1988 Mar;62(3):687–695.[PMC free article] [PubMed] [Google Scholar]
  • Rothbard J. Synthetic peptides as vaccines. Nature. 1987 Nov 12;330(6144):106–107. [PubMed] [Google Scholar]
Institute of Pathology, University Hospital, Zürich, Switzerland.
Institute of Pathology, University Hospital, Zürich, Switzerland.
Copyright notice
Abstract
A specific antiviral cytotoxic immune response in vivo could be induced by the subcutaneous injection of the T-cell epitope of the lymphocytic choriomeningitis virus (LCMV) nucleoprotein as an unmodified free synthetic peptide (Arg-Pro-Gln-Ala-Ser-Gly-Val-Tyr-Met-Gly-Asn-Leu-Thr-Ala-Gln) emulsified in incomplete Freund's adjuvant. This immunization rendered mice into a LCMV-specific protective state as shown by the inhibition of LCMV replication in spleens of such mice. The protection level of these mice correlated with the ability to respond to the peptide challenge by CD8+ virus-specific cytotoxic T cells. This is a direct demonstration that peptide vaccines can be antivirally protective in vivo, thus encouraging further search for appropriate mixtures of stable peptides that may be used as T-cell vaccines.
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.